Your recent reading points toward a clear frame: deep tech is not only a technology problem; it is a capital-structure problem. The hard part is not simply inventing better biology, AI systems, chips, robotics, energy assets, or industrial infrastructure. The hard part is matching each technical risk profile with a financing instrument that can survive the time, uncertainty, capex, regulatory drag, and market-formation work required to make the innovation real.
Across your VC Landscape & News and Papers - Computation & Investing databases, the recurring pattern is this:
The frontier of innovation is becoming more expensive, more physical, more regulated, and more strategically important — while traditional venture capital remains structurally best suited for software-like risk: fast iteration, low marginal cost, short feedback loops, and clean exit paths.
That mismatch is forcing a migration from “VC as default capital” toward a richer toolkit: portfolio finance, synthetic royalties, project finance, venture debt, government-backed de-risking, structured contracts, strategic offtake, industrial policy, and asset-backed financing.
The most important question your reading raises is not “Can finance help deep tech?” It is sharper:
Which parts of deep tech should be made more financially legible — and which parts become dangerous when finance makes them too legible?
That is the Parikshit-flavored crux.
Your recent library clusters into five overlapping domains.
The core piece here is “Curious cases of financial engineering in biotech”, which is basically a tour of how finance has colonized every surface of drug development: portfolios, royalties, regulatory vouchers, M&A earnouts, and even failed public shells.[1]
The essay’s starting point is brutally simple: drug development resembles a terrible lottery ticket — huge cost, long duration, very low probability of success, but enormous payoff if it works. The problem is not that the expected value is always negative. The problem is that most investors cannot survive the variance.[1]
That leads to Andrew Lo’s key idea: bundle many independent drug programs into a large portfolio, reduce idiosyncratic risk, and potentially issue debt against the portfolio. In theory, this lets biomedical innovation tap the much larger pool of institutional fixed-income capital, not just venture equity.[1]
The essay then follows the practical descendants and deviations: